timothy sykes logo
MRNA Stock Climbs As Oncology Catalysts And Upgrades Pile Up Thumbnail
G Google News

MRNA Stock Climbs As Oncology Catalysts And Upgrades Pile Up

ELLIS HOBBS•UPDATED SEP. 11, 2026, 12:32 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Moderna Inc. stocks have been trading up by 9.29 percent amid strong investor enthusiasm for its latest mRNA vaccine advances.

Key Takeaways Traders Are Watching

  • Argus upgraded Moderna to Buy with a $180 target after FDA approval of updated 2026-2027 COVID-19 shots, as MRNA now has five mRNA products approved across major respiratory diseases.
  • An upsized $2.6B 0% convertible notes deal, plus a $400M greenshoe, gives Moderna fresh capital for oncology while capped calls help limit dilution up to a 175% share-price premium.
  • UBS flagged upcoming individualized neoantigen readouts, led by phase 3 melanoma data this fall, as key MRNA stock catalysts while holding a Neutral rating and $150 target.
  • Evercore ISI raised its MRNA target to $80 from $50 but kept an In Line stance, as the broader Street still sits at a Hold consensus and a $108 average price target.
  • Morgan Stanley sees limited read-across from negative BioNTech colorectal data to Moderna’s mRNA cancer vaccines, which recently posted positive late-stage skin cancer results.

Candlestick Chart

Live Update At 12:32:09 EDT: On Friday, September 11, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 9.29%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA has been trading like a high-speed rollercoaster. In mid-August the stock changed hands near $63, then ripped to an intraday high above $176 on 2026/08/19, and now sits around $149 after a strong push from $134 this week. That is serious momentum for active trading.

The daily chart shows a series of higher lows from late August, with MRNA bouncing hard every time it dips toward the $135–$140 zone. That area now acts like a key support band that short-term traders are watching closely. On 2026/09/11, the stock opened near $138 and ran to $149.26, closing near the highs — strong trend-day behavior.

Intraday, the 5‑minute tape shows steady stair-step buying from the $136 pre-market area up through the high $140s. Pullbacks have been shallow and met with quick bids, hinting that dip buyers currently control MRNA. Fundamentally, trailing revenue of about $1.92B and a price-to-sales near 24 show the market is paying up for future growth, not current profits.

More Breaking News

Margins are deeply negative and free cash flow was roughly -$563M last quarter, so MRNA is still a story stock. But with over $5.1B in cash and short-term investments and a current ratio of 2.3, the balance sheet gives the company room to keep funding its pipeline — fuel for longer-term traders betting on oncology and vaccines.

Why Traders Are Laser-Focused On MRNA Right Now

The real spark behind MRNA’s latest run is not just the chart. It is the news flow. Argus stepped up with a Buy rating and a $180 price target after FDA approval of Moderna’s updated 2026-2027 COVID-19 vaccines. That approval means Moderna now has five commercial mRNA products across COVID-19, combo flu/COVID-19, RSV, and influenza. For traders, that translates to a clearer revenue base beyond the pandemic spike-and-crash pattern.

MRNA also scored an important win in cancer. The company reported positive topline results from a late-stage mRNA-based skin cancer program. At the same time, BioNTech had to discontinue a colorectal cancer trial, and Morgan Stanley explicitly said that setback does not spill over to Moderna’s platform. That kind of differentiation matters; traders are hunting for which mRNA player can actually turn oncology into real sales.

UBS added more fuel by calling out three upcoming individualized neoantigen therapy readouts as major stock catalysts. The big one is phase 3 melanoma data expected this fall, with renal cell carcinoma or bladder cancer updates around 2027 and a non-small cell lung cancer phase 3 update further out. UBS still sits at Neutral with a $150 target while MRNA trades just under that level. That tells traders the Street sees event risk both ways — expect big moves when those data hit.

Behind the scenes, Moderna’s capital move matters too. The company upsized a 0% convertible notes deal to $2.6B, plus a $400M greenshoe, with conversion set roughly 47.5% above the current share price. MRNA also bought capped call hedges to offset dilution up to a 175% premium. Translation: institutional money was willing to fund the story at a steep premium, and management tried to protect common shareholders from near-term dilution. For momentum traders, that is another confidence signal.

Conclusion

MRNA is shifting from a one-hit COVID story into a broader mRNA platform trade, and the tape reflects that shift. Argus’s Buy rating and $180 target stand well above the current consensus near $108, while UBS’s $150 and Evercore’s $80 show just how wide the range of views remains. This spread in targets is exactly why MRNA trading remains volatile — the Street still argues over what long-term earnings will look like once oncology and combo vaccines scale.

Fundamentals are not pretty today. Last quarter MRNA posted about $143M in revenue and a net loss of roughly $782M, with heavy R&D spend near $651M. Those numbers scare off conservative money. But for active traders, they highlight what the market is truly pricing: the chance that melanoma, lung, and other cancer programs become multi-year growth drivers.

With more than $5B in liquidity plus the new $2.6B convertibles, Moderna has time to prove that out. Upcoming phase 3 melanoma data sit right in the crosshairs. Any clear beat can justify targets closer to Argus’s $180; a disappointment can drag the stock back toward the lower end of the current target range.

For traders, the game plan around a name like MRNA is about discipline. As Tim Sykes likes to remind his students, “the best traders aren’t prophets, they’re risk managers who cut losses quickly and let the best setups play out.” As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. That mindset is crucial when a catalyst-heavy ticker like MRNA can gap sharply in either direction. MRNA’s setup right now is all about catalysts, liquidity, and a hot chart — study the levels, know the dates, and treat every trade as a planned trade, not a prediction.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”